Dysfunctional Uterine Bleeding Market– Growing awareness likely to result in handsome CAGR growth

The Global Dysfunctional Uterine Bleeding Market Synopsis:

Dysfunctional uterine bleeding (DUB) is abnormal genital tract bleeding based in the uterus without the presence of any structural or organic disease. Although the exact reason is unknown, it is usually a menstrual disorder due to hormonal disturbances such as reduced progesterone levels, increased levels of tissue plasminogen activator and others. However there are cases of abnormal bleeding from the uterus outside menstruation. The global Dysfunctional Uterine Bleeding Market is expected to grow at a CAGR of 7.6 % during the forecast period of 2017 to 2023

DUB is classified as ovulatory or anovulatory, depending on whether ovulation is occurring or not. 10% of cases occur in women who are ovulating, called as ovulatory DUB. About 90% of DUB is anovulatory with events occur when ovulation is not occurring and is common at the extremes of reproductive age, such as early puberty and perimenopause. The risk factors are psychological stress, weight changes such as obesity, anorexia, heavy exercise, endocrinopathy, neoplasm, drugs, etc. increasing cases of fibroids in the uterus, infection of the cervix, cancer of the uterus, polycystic ovary syndrome, endometriosis, and uterine polyps are also firing the growth of the market. According to the World Cancer Research Fund International, endometrial cancer is the sixth most common cancer in women worldwide, in 2015, with 53% of endometrial cancer cases occurring in the developed countries.

Key Players in the Global Dysfunctional Uterine Bleeding Market       

·         B. Braun Melsungen AG

·         Hologic Inc

·         Karl Storz Gmbh & Co. KG

·         Medgyn Products

·         Olympus

·         Richard Wolf GmbH

·         Stryker

·         Xion Medical GmbH

·         Cadila Pharmaceuticals Ltd

·         Torrent Phamraceuticals

Segments of the Global Dysfunctional Uterine Bleeding Market

·         Dysfunctional uterine bleeding market is segmented into type, diagnosis, and treatment.

·         On the basis of type the market is sub-segmented into ovulatory and anovulatory.

·         On the basis of diagnosis, the market is sub-segmented into physical examination, hysteroscopy, ultrasonography, blood tests and others.

·         On the basis of treatment  the market is sub-segmented into pharmacologic treatment, hysterectomy, endometrial ablation and others.

Regional outlook of the dysfunctional uterine bleeding market

America is the largest market for dysfunctional uterine bleeding market across the globe. The market is driven by the rising prevalence of uterine cancer and other uterine disorders among women. According to the American Cancer Institute, about 61,380 new cases of uterine cancer is estimated to be diagnosed in 2017. Europe is the second largest market owing to an increasing demand for diagnosis and treatment measures for uterine cancer, fibroids and other disorders, and increasing emphasis on women healthcare.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing prevalence of menstrual disorders, rising awareness about causes of such disorders and early diagnosis and treatment measures among women. The market is also driven by rising prevalence of sexually transmitted diseases among women in the developing nations. Rising awareness is the key to the market as a large unmet need is present in the developing regions which has not been tapped due to the stigma associated with women gynaecological disorders.